Detalhe da pesquisa
1.
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med
; 390(4): 301-313, 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38084760
2.
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma.
Haematologica
; 2024 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38385280
3.
Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA.
Am J Hematol
; 99(3): 396-407, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38298023
4.
Incidence and risk factors for central nervous system relapse in patients with primary mediastinal large B-cell lymphoma in the rituximab era.
Hematol Oncol
; 41(1): 97-107, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36314897
5.
Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab-based quadruplets: A multicenter study by the Greek myeloma study group.
Am J Hematol
; 98(5): 730-738, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36869876
6.
Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial.
Am J Hematol
; 97(4): 481-490, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35089607
7.
Chromosome 1q21 aberrations identify ultra high-risk myeloma with prognostic and clinical implications.
Am J Hematol
; 97(9): 1142-1149, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35731917
8.
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(6): 801-812, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34087126
9.
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Lancet
; 396(10262): 1563-1573, 2020 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33189178
10.
Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP.
Oncologist
; 26(7): 597-609, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33870594
11.
Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas.
Hematol Oncol
; 39(3): 336-348, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33583077
12.
Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies.
Ann Hematol
; 100(9): 2279-2292, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-33523289
13.
Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma.
Ann Hematol
; 99(5): 1049-1061, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-32236735
14.
Real-world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco-Israeli collaborative myeloma working group.
Am J Hematol
; 95(5): 465-471, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32048329
15.
Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma.
Int J Cancer
; 145(2): 559-568, 2019 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30650184
16.
Evaluation of regulatory T cells (Tregs) alterations in patients with multiple myeloma treated with bortezomib or lenalidomide plus dexamethasone: correlations with treatment outcome.
Ann Hematol
; 98(6): 1457-1466, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30895351
17.
Correction to: Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.
Ann Hematol
; 97(9): 1747, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29943159
18.
Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.
Ann Hematol
; 97(9): 1671-1682, 2018 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-29756171
19.
Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice.
Eur J Haematol
; 101(4): 556-565, 2018 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-30027641
20.
Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study.
Am J Hematol
; 98(9): E226-E229, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37340832